Medical licensing is commonly viewed as a means to protect consumers from harmful medical practices. However, it has been argued that its true purpose is to protect the financial interests of specific medical organizations, particularly those allied with the pharmaceutical industry, contributing to rising healthcare costs and poor health outcomes.
1. Misconception About Medical Licensing:
• Medical licensing is believed to protect consumers from "quacks" and improve healthcare quality. However, the system has failed to deliver better patient outcomes.
• The central purpose is posited to be the protection of the financial interests of trade organizations, particularly the American Medical Association (AMA) and pharmaceutical companies.
2. Historical Context:
• Early U. S. medical licensing laws favored allopathic practitioners and marginalized alternative medicine, even when mainstream treatments like bloodletting were standard.
• A push for repealing restrictive licensing led to lower prices and better healthcare outcomes in the 1800s until the AMA was formed in 1847 to establish a monopoly over medical practice.
3. The AMA's Strategy:
• The AMA sought to reduce competition by limiting the number of medical schools and controlling the practice of medicine through licensing.
• Licensing was portrayed as necessary for consumer protection, claiming that individuals could not make informed health choices.
4. Judicial Support for Licensing:
• The U. S. Supreme Court supported the legitimacy of restrictive licensing laws through cases that favored the AMA's interests over individual rights and consumer choice.
5. The Flexner Report:
• The 1910 Flexner Report, commissioned by the Carnegie Foundation at the AMA's behest, led to the closure of many medical schools and emphasized a curriculum that aligned with the interests of pharmaceutical companies.
• This report is credited with reforming medical education, but it primarily served to restrict competition and promote a drug-centric approach to health care.
6. Impact on Medical Research:
• The AMA and pharmaceutical alliance shifted medical research toward a focus on pharmacological treatments rather than more holistic or preventative approaches.
• Conflicts of interest have plagued medical science, pushing a narrative that ignored the social determinants of health that contributed to improvements in health outcomes.
7. Inflated Claims of Medical Achievements:
• The narrative that modern medical interventions, such as vaccines, significantly reduced mortality rates is challenged by historical data showing improvements were already occurring due to factors like better living conditions and hygiene.
8. Informed Consent and Autonomy:
• Licensing restricts ethical physicians who respect parental rights in medical decisions, particularly regarding childhood vaccinations.
• The licensing regime undermines personal autonomy, reducing consumer choice and voicing concerns about quality of care.
9. Consequences of Medical Licensing:
• Licensing leads to a restricted number of physicians, higher healthcare costs, stagnated innovation in research, and poor health outcomes.
• The system emphasizes conformity to “standard of care” instead of clinical performance and patient outcomes.
The current medical licensing framework is seen as a system designed to limit supply and suppress competition rather than improve healthcare quality. Abolishing medical licensing is proposed as a radical yet essential solution to restore consumer choice and promote a healthier population. Existing market standards for education and certification would remain in place without the governmental constraints of licensing bodies. The need for reform stems from the desire to liberate patients from a government-backed medical cartel and to rectify the unsustainable financial and health-related crises associated with current practices in the healthcare system. The solution lies in eliminating government involvement in health care to foster a more effective and patient-centered approach.
https://mises.org/mises-wire/how-medical-licensing-serves-big-pharma-expense-public-health
No comments:
Post a Comment